China Steps Towards International M & A  

Oleh:

Hepeng Jia

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 2 (Feb. 2005), page 159-160.
Topik: INTERNATIONAL; china steps; international

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Invitrogen's acquisition of chinese competitor bioasia is the first major acquisition by a foreign compaby in the life science sector. The move has been made possible by recent changes in the chinese legal framework surrounding margers and acquisitions (M & A) by foreign companies in China. Although until now, foreign biotech companies have been mainly interested in outsourcing productions M & A by foreign biotech companies have been mainly interested in outsourcing production and some aspect of their research programs to the country, opportunities in acquiring R & D capabilities may not be quite ripe yet. Intivitrogen of Carlsbad, California, a provider of biotech research equipment and reagents, acquired chinese sequencing reagent company bioasia of shanghai in december 2004 for US$ 8 million, thus acquiring 18 sales offices across china...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali